Antinucleosome Antibodies and Decreased Deoxyribonuclease Activity in Sera of Patients with Systemic Lupus Erythematosus
Antinucleosome Antibodies and Decreased Deoxyribonuclease Activity in Sera of Patients with Systemic Lupus Erythematosus
复制标题
系统性红斑狼疮患者血清中的抗核小体抗体和脱氧核糖核酸酶活性降低
DOI：
--
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
P. Gergely
中科院分区：
文献类型：
--
作者：
K. Sallai;E. Nagy;Beata Derfalvy;G. Müzes;P. Gergely
核小体是系统性红斑狼疮（SLE）患者的主要自身抗原，核小体免疫复合物是导致组织损伤的主要原因。已发现SLE患者中负责核小体降解的DNA酶I的活性降低。然而，尚不清楚DNA酶活性是否是临床上有用的参数。本研究的目的是评估113例SLE患者的DNA酶活性与疾病活动和器官受累的关系。我们包括两个对照组：9例未分化结缔组织病（UCTD）患者和14名健康人。SLE患者血清DNA酶活性（63.75% ± 12.1%）明显低于对照组（81.3% ± 9.25%）（P < 0.001）。UCTD患者的DNA酶活性（64.9% ± 18.2%; P = 0.854）与SLE患者无差异。SLE患者抗核小体抗体滴度（356.3 ± 851）高于对照组（1.44 ± 2.77; P < 0.01）和UCTD患者（39.9 ± 57.7; P < 0.01）。此外，抗核小体抗体阳性的样品显示低水平的DNA酶活性。在SLE组中，肾脏疾病的存在对DNA酶活性或抗核小体抗体滴度没有影响。SLE疾病活动指数与DNA酶活性无相关性。在一项对6名SLE患者的纵向研究中，DNA酶活性并不跟随疾病活动或自身抗体滴度。我们的研究结果证实，血清DNA酶活性降低SLE患者，但我们的结论是，它不是一个临床上有用的参数，用于预测疾病的突发或肾脏受累。
ABSTRACT Nucleosomes are the dominant autoantigens in patients with systemic lupus erythematosus (SLE), and immune complexes involving nucleosomes are the major cause of tissue damage. The activity of DNase I, the enzyme responsible for nucleosome degradation, has been found to be decreased in patients with SLE. However, it is not known whether DNase activity is a clinically useful parameter. The aim of our study was to assess DNase activity in a prospective study of 113 patients with SLE in relation to disease activity and organ involvement. We included two control groups: 9 patients with undifferentiated connective tissue disease (UCTD) and 14 healthy individuals. DNase activity was found to be lower in patients with SLE (63.75% ± 12.1%) than in the controls (81.3% ± 9.25%) (P < 0.001). DNase activity in patients with UCTD (64.9% ± 18.2%; P = 0.854) did not differ from that in patients with SLE. Patients with SLE had higher antinucleosome antibody titers (356.3 ± 851) than the controls (1.44 ± 2.77; P < 0.01) or UCTD patients (39.9 ± 57.7; P < 0.01). In addition, samples positive for antinucleosome antibodies displayed low levels of DNase activity. Within the SLE group, the presence of renal disease had no impact on DNase activity or antinucleosome antibody titers. Also, the SLE disease activity index showed no correlation with DNase activity. In a longitudinal study of six SLE patients, DNase activity did not follow disease activity or autoantibody titers. Our results confirm that serum DNase activity is decreased in patients with SLE, but we conclude that it is not a clinically useful parameter for the prediction of flare-ups of disease or renal involvement.